arrow
M

Mark Verrill

Newcastle upon Tyne Hospitals NHS Foundation Trust
H指数:30
被引数:3,927

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma The PROACT Clinical Trial

预防接受乳腺癌和淋巴瘤治疗的患者的心脏损伤PROACT临床试验

2024-10-011
OA
A UK prospective multicentre decision impact, decision conflict and economic evaluation of the use of Oncotype DX® to guide chemotherapy in 680 women with hormone receptor positive, HER2 negative breast cancer and 1 to 3 nodes involved
2023-03-010
PRE
Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer
BREAST
IF7.9
2022-12-014
OAAI
Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study
BREAST
IF7.9
2021-12-0116
OAAI
Palbociclib combined with aromatase inhibitors (AIs) in women ≥75 years with oestrogen receptor positive (ER plus ve), human epidermal growth factor receptor 2 negative (HER2-ve) advanced breast cancer: A real-world multicentre UK study
2021-09-010
OAAI
Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage

英国HER2-positive乳腺癌患者的健康相关生活质量和工作效率: 一项评估疾病与治疗阶段之间关系的横断面研究

2020-11-0219
OAAI
Impact of the Oncotype DX breast cancer assay on treatment decisions in a UK population of patients with oestrogen receptor positive early breast cancer with 1-3 lymph nodes positive who are candidates for chemotherapy, but for whom the benefits are uncertain - Interim results
2020-02-152
PRE
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

帕妥珠单抗联合曲妥珠单抗和紫杉烷一线治疗HER2-positive局部复发或转移性乳腺癌的初步安全性和有效性 (PERUSE)

2019-05-0189
OAAI
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

帕妥珠单抗、曲妥珠单抗和以蒽环类和紫杉烷为基础的标准化疗用于HER2-positive局部乳腺癌患者的新辅助治疗 (BERENICE): 一项II期、开放标签、多中心、跨国心脏安全性研究

2018-03-01182
OAAI